ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig.
性状
Solid
体外研究(In Vitro)
ONO 1301 (ONO-AP 500-02) inhibits collagen-induced aggregation in a concentration-dependent manner, with an IC50 value of 460 nM.ONO-1301 (0-1000 nM) significantly increases alkaline phosphatase (ALP) activity in the primary osteoblasts and ST2 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
ONO-1301 (6 mg/kg; p.o.; /daily for 4 weeks) improves the hemodynamic status of rats with dilated cardiomyopathy after experimental autoimmune myocarditis. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;In solvent -80°C 6 months
参考文献
[1]. Hirata Y, et al. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013;699(1-3):81-87. [2]. Kashiwagi H, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353(2):269-278.
溶解度数据
In Vitro: DMSO : 50 mg/mL (116.69 mM; Need ultrasonic)配制储备液